Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 0.45 |
| ▸ | F3 | P13726 | 20/20 | 0.45 |
| ▸ | F2 | P00734 | 9/20 | 0.44 |
| ▸ | F10 | P00742 | 9/20 | 0.44 |
| ▸ | F11 | P03951 | 9/20 | 0.44 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910772 | 0.87 | MEN1 (0.43) | F7F3F2F10F11 | |
| SCHEMBL2914617 | 0.87 | MEN1 (0.43) | F7F3F2F10F11 | |
| SCHEMBL2910770 | 0.87 | MEN1 (0.43) | F7F3F2F10F11 | |
| SCHEMBL2911226 | 0.85 | RIPK1 (0.38) | F7F3 | |
| SCHEMBL2916156 | 0.83 | RIPK1 (0.45) | F7F3F2F10F11 | |
| SCHEMBL4110657 | 0.76 | F7 (0.39) | F7F3F2F10F11 | |
| SCHEMBL3092910 | 0.72 | PPID (0.37) | — | |
| SCHEMBL13613597 | 0.72 | NR1H2 (0.43) | — | |
| SCHEMBL13613594 | 0.72 | NR1H2 (0.43) | — | |
| SCHEMBL13613598 | 0.72 | NR1H2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061756-B1 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8222453-B2 | Benzamide factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-09 | — | — | US | disclosed |
| EP-1856096-B1 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2061756-A2 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENILACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2007146719-A2 | 2-AMINOCARBONYLPHENYLAMINO-2-PHENYLACETAMIDES AS FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1856096-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Bristol-Myers Squibb Company (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | F7 35/4885F3 20/4885F2 9/4885 |
| US-20100227894-A1 | BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F9, F8 | F7 1/4885F3 10/4885F2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.